Y Intercept Hong Kong Ltd Buys 601,178 Shares of Roivant Sciences Ltd. $ROIV

Y Intercept Hong Kong Ltd boosted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 221.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 873,081 shares of the company’s stock after purchasing an additional 601,178 shares during the quarter. Y Intercept Hong Kong Ltd owned about 0.13% of Roivant Sciences worth $13,210,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. CWM LLC grew its stake in Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after buying an additional 920 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in Roivant Sciences by 204.2% during the second quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock valued at $65,000 after acquiring an additional 3,882 shares during the period. UMB Bank n.a. grew its position in shares of Roivant Sciences by 42.0% in the second quarter. UMB Bank n.a. now owns 5,883 shares of the company’s stock valued at $66,000 after purchasing an additional 1,740 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Roivant Sciences by 22.9% in the second quarter. GAMMA Investing LLC now owns 7,978 shares of the company’s stock worth $90,000 after purchasing an additional 1,485 shares during the period. Finally, Rossby Financial LCC bought a new position in shares of Roivant Sciences in the second quarter worth about $113,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

NASDAQ:ROIV opened at $22.58 on Friday. The company has a 50-day moving average of $21.72 and a 200-day moving average of $17.01. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $23.91. The company has a market capitalization of $15.70 billion, a price-to-earnings ratio of -40.32 and a beta of 1.22.

Insider Activity at Roivant Sciences

In other news, insider Mayukh Sukhatme sold 1,018,995 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $21.71, for a total value of $22,122,381.45. Following the sale, the insider directly owned 20,267,429 shares in the company, valued at approximately $440,005,883.59. This represents a 4.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Richard Pulik sold 406,731 shares of the firm’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $22.43, for a total value of $9,122,976.33. Following the transaction, the chief financial officer owned 239,413 shares of the company’s stock, valued at $5,370,033.59. This trade represents a 62.95% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 12,332,392 shares of company stock valued at $266,393,645. Corporate insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Roivant Sciences in a report on Thursday. Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Leerink Partners boosted their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Guggenheim reiterated a “buy” rating and set a $28.00 target price on shares of Roivant Sciences in a research note on Thursday, December 18th. Finally, Citigroup raised their price target on shares of Roivant Sciences from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Roivant Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $25.19.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.